Weight loss drugs have surged in popularity. But Gov. Ned Lamont wants CT’s Medicaid program to discontinue covering them for ...

In 2023, the United States marked a major milestone in the battle against a longstanding public health crisis: adult obesity rates dropped for the first time in a decade. Researchers pointed to GLP-1s ...

New weight loss drugs like Ozempic and Wegovy help suppress appetite, leading to significant weight loss, but they come with ...

Dawn Maroney became president of Alignment Health in January at a critical time for the health insurance industry.

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff ...

Spring has nearly sprung and round two of the Inflation Reduction Act (IRA)’s negotiation period has begun. | All of the ...

A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and ...

While weight-loss drugs like Zepbound (LLY) and Wegovy (NVO) offer significant health benefits, their high costs make them economically inefficient under current U.S. healthcare standards, according ...

Wegovy is a prescription medication designed for chronic weight management, offering hope to individuals struggling with ...

They’re expensive and aren’t a short-term fix, but Ozempic and Wegovy show great promise in regulating weight. | Opinion ...